MG
KYNB

Michael Gelband’s Kyntra Bio KYNB Stock Holding History

Michael Gelband’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-733
Closed -$342K – 1973
2023
Q1 		$342K Sell
733
-3,701
-83% -$1.96M ﹤0.01% 1435
2022
Q4 		$1.78M Buy
+4,434
New +$1.7M 0.03% 695
2022
Q2 		– Sell
-4,469
Closed -$1.34M – 2088
2022
Q1 		$1.34M Buy
4,469
+2,701
+153% +$942K 0.02% 974
2021
Q4 		$623K Sell
1,768
-492
-22% -$153K 0.01% 1280
2021
Q3 		$577K Buy
+2,260
New +$801K 0.01% 1298
2021
Q2 		– Sell
-623
Closed -$541K – 2494
2021
Q1 		$541K Buy
+623
New +$663K 0.01% 1292
2020
Q4 		– Sell
-235
Closed -$242K – 2088
2020
Q3 		$242K Buy
+235
New +$253K ﹤0.01% 1389

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's KYNB Position: Q2 2023 in Review

Michael Gelband sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 733 shares — an estimated $342K sold.

Michael Gelband first reported a position in KYNB in Q3 2020 and held it in 7 quarters. The position peaked at $1.78M in Q4 2022. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

  • Michael Gelband reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
  • Michael Gelband sold 733 Kyntra Bio shares in Q2 2023, an estimated $342K.
  • Michael Gelband first reported a position in Kyntra Bio in Q3 2020 and held it in 7 quarters.
  • Michael Gelband's Kyntra Bio position peaked at $1.78M in Q4 2022.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on ExodusPoint Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.